Cart (0)
Your shopping cart is empty!
Out of Stock
interferon alfa-2b | Viferon rectal suppositories 1,000,000 IU, 10 pcs.
interferon alfa-2b | Viferon rectal suppositories 1,000,000 IU, 10 pcs.
Product Code: 835

interferon alfa-2b | Viferon rectal suppositories 1,000,000 IU, 10 pcs.

Compare this Product
Out Of Stock
Release form

Rectal suppositories.


10 pcs.

Pharmacological action

Interferon alfa-2b human recombinant has antiviral, immunomodulating, antiproliferative properties, inhibits the replication of RNA and DNA viruses. The immunomodulating properties of interferon alpha-2b, such as increased macrophage phagocytic activity, increased specific cytotoxicity of lymphocytes to target cells, determine its mediated antibacterial activity.

In the presence of ascorbic acid and alpha-tocopherol acetate, the specific antiviral activity of interferon alpha-2b increases, its immunomodulatory effect is enhanced, which allows to increase the efficiency of the body's own immune response to pathogenic microorganisms. When using the drug, the level of secretory immunoglobulins of class A increases, the level of immunoglobulin E is normalized, the functioning of the endogenous system of interferon alpha-2b is restored. Ascorbic acid and alpha-tocopherol acetate, being highly active antioxidants, have anti-inflammatory, membrane-stabilizing, and also regenerating properties. It has been established that when using the VIFERON® preparation, there are no side effects arising from the parenteral administration of interferon alpha-2b preparations, antibodies are not formed that neutralize the antiviral activity of interferon alpha-2b. The use of VIFERON® as part of complex therapy allows to reduce therapeutic doses of antibacterial and hormonal drugs, as well as reduce the toxic effects of this therapy.

Cocoa butter contains phospholipids, which allow synthetic toxic emulsifiers not to be used in production, and the presence of polyunsaturated fatty acids facilitates the administration and dissolution of the drug.


- acute respiratory viral infections, including influenza, including complicated by a bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of the complex therapy

- infectious and inflammatory diseases of newborns, including premature infants: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis) as part of

complex therapy - chronic viral hepatitis B, C, D in children and adults in the composition of complex therapy, including in combination with the use of plasmapheresis and hemosorption in case of chronic viral hepatitis of pronounced activity complicated by liver cirrhosis

- infectious and inflammatory diseases of the urogenital tract (trash IPH, cytomegalovirus infection, ureaplasmosis, trichomoniasis, bacterial vaginosis, HPV infection, bacterial vaginosis, recurrent vaginal candidiasis, a mycoplasmosis) in adults as part of combination therapy

- primary or recurrent herpetic infection of the skin and mucous membranes, localized form, mild and moderate course, including the urogenital form in adults.


Hypersensitivity to the components of the drug.

Special instructions

For the treatment of a wide range of infectious and inflammatory diseases Viferon can be used as part of combination therapy with antibacterial drugs, glucocorticoids, immunosuppressive drugs.

There is evidence of the effectiveness of the use of Viferon as part of complex therapy and for the prevention of the following diseases and conditions: herpetic infections, chlamydia, ureaplasmosis, toxoplasmosis, cytomegalovirus infection in adults and children over 1 year old, viral hepatitis in adults, SARS, influenza, bronchial asthma, juvenile rheumatoid arthritis meningeal form of tick-borne encephalitis prostatitis of various etiologies purulent-septic postoperative complications, virus-associated glomerulonephritis, pyelonephus rits.


1 suppository VIFERONΠ1,000,000 IU contains the active substance: interferon alpha-2b human recombinant 1,000,000 IU, excipients: ascorbic acid 0,0081 g, sodium ascorbate 0,0162 g, alpha-tocopherol acetate 0,055 g, disodium dihydride 0.0001 g, polysorbate-80 0.0001 g, cocoa butter 0.1941 g, confectionery fat or cocoa butter substitute up to 1 g.

Side effects of

In rare cases, the development of allergic reactions (skin rashes, itching) is possible

Drug Interactions

VIFERON®, rectal suppositories, is compatible and well combined with all drugs used in the treatment of the above diseases (antibiotics, chemotherapy, glucocorticosteroids).

Storage Conditions

The product should be stored in a dry, dark place at 2 ° to 8 РC.


2 years.

Terms leave through pharmacies

without prescription

lekarstvennaja form

suppozytoryy rektaln e


Vaginal candidiasis, Vaginal infections, Urinary tract infections, Herpes, HPV, Chlamydia, Hepatitis, Influenza

Possible Product Names

Viferon 1000000 IU Supp. rect. X10 (R)

Viferon 3 1000 thousand IU No. 10 supp

Viferon suppositories 1 million IU No. 10

Viferon rectal suppositories 1 000 000 IU, 10 pieces.

Viferon rectal suppositories 1,000,000 IU, 10 pcs.

Fearon, Russia